TEVA PHARMACEUTICAL INDUSTRIES LTD Gross Profit

Quick Answer

TEVA PHARMACEUTICAL INDUSTRIES LTD reported Gross Profit of $8.94 billion for the year ending 2025.

  • TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +10.8% in Gross Profit from 2024 to 2025.
  • This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
  • XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2016: $2.79 billion | Q2 2016: $2.88 billion | Q3 2016: $2.80 billion | Q4 2016: $3.39 billion | Q1 2017: $2.77 billion | Q2 2017: $2.80 billion | Q3 2017: $2.60 billion | Q4 2017: $2.44 billion | Q1 2018: $2.32 billion | Q2 2018: $2.03 billion | Q3 2018: $1.98 billion | Q4 2018: $1.97 billion | Q1 2019: $1.86 billion | Q2 2019: $1.89 billion | Q3 2019: $1.83 billion | Q4 2019: $1.96 billion | Q1 2020: $2.06 billion | Q2 2020: $1.76 billion | Q3 2020: $1.85 billion | Q4 2020: $2.05 billion | Q1 2021: $1.88 billion | Q2 2021: $1.87 billion | Q3 2021: $1.79 billion | Q1 2022: $1.74 billion | Q2 2022: $1.79 billion | Q3 2022: $1.67 billion | Q1 2023: $1.58 billion | Q2 2023: $1.80 billion | Q3 2023: $1.85 billion | Q1 2024: $1.77 billion | Q2 2024: $2.02 billion | Q3 2024: $2.15 billion | Q1 2025: $1.88 billion | Q2 2025: $2.10 billion | Q3 2025: $2.30 billion.
  • Over the full 18 years of available data (2008 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Gross Profit has grown by 49.8%.
  • Historical annual values: Fiscal year 2025: $8.94 billion | Fiscal year 2024: $8.06 billion | Fiscal year 2023: $7.65 billion | Fiscal year 2022: $6.97 billion | Fiscal year 2021: $7.59 billion | Fiscal year 2020: $7.73 billion | Fiscal year 2019: $7.54 billion | Fiscal year 2018: $8.30 billion | Fiscal year 2017: $10.62 billion | Fiscal year 2016: $11.65 billion | Fiscal year 2015: $11.36 billion | Fiscal year 2014: $11.06 billion | Fiscal year 2013: $10.71 billion | Fiscal year 2012: $10.65 billion | Fiscal year 2011: $9.52 billion | Fiscal year 2010: $9.07 billion | Fiscal year 2009: $7.37 billion | Fiscal year 2008: $5.97 billion.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: